Kolltan Pharmaceuticals Joins Celldex Therapeutics

Celldex Therapeutics acquired Kolltan Pharmaceuticals on November 29, 2016.

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

Visit Celldex.com to learn more about us.